Evidence map›Paper›PMID 30737368›Full record

ArticleCell death & disease2019

Disruption of the FasL/Fas axis protects against inflammation-derived tumorigenesis in chronic liver disease.

Francisco Javier Cubero, Marius Maximilian Woitok, Miguel E Zoubek, Alain de Bruin, Maximilian Hatting, Christian Trautwein

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Francisco Javier CuberoDepartment of Internal Medicine III, University Hospital, RWTH Aachen, Aachen, Germany. fcubero@ucm.es.
Marius Maximilian WoitokDepartment of Internal Medicine III, University Hospital, RWTH Aachen, Aachen, Germany.
Miguel E ZoubekDepartment of Internal Medicine III, University Hospital, RWTH Aachen, Aachen, Germany.
Alain de BruinDepartment of Toxicology, Faculty of Health Medicine and Life Sciences, School of Nutrition, Toxicology and Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands.
Maximilian HattingDepartment of Internal Medicine III, University Hospital, RWTH Aachen, Aachen, Germany.
Christian TrautweinDepartment of Internal Medicine III, University Hospital, RWTH Aachen, Aachen, Germany. ctrautwein@ukaachen.de.
RWTH Aachen University · DEMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fas Ligand (FasL) and Fas (APO-1/CD95) are members of the TNFR superfamily and may trigger apoptosis. Here, we aimed to elucidate the functional role of Fas signaling in an experimental model of chronic liver disease, the hepatocyte-specific NEMO knockout (NEMO

Indexed as

AnimalsCarcinogenesisChronic DiseaseFas Ligand Proteinfas ReceptorIntracellular Signaling Peptides and ProteinsLiverLiver DiseasesLiver NeoplasmsMaleMiceMice, KnockoutMice, TransgenicFas Ligand ProteinFasl protein, mouseFas protein, mousefas ReceptorIntracellular Signaling Peptides and ProteinsNEMO protein, mouse

Identifiers

PMID30737368
PMCPMC6368573
OpenAlexW2913568968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.